Here are the 10-K annual reports from Structure Therapeutics Inc. (GPCR) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow GPCR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GPCR filings page.
Structure Therapeutics is a clinical-stage biopharma company using structure-based design and computational chemistry to create oral small molecules that target GPCRs for chronic diseases, with a major focus on obesity and metabolic disorders.
The lead candidate, aleniglipron, an oral GLP‑1 receptor agonist, delivered placebo‑adjusted mean weight loss of 11.3% at 120 mg in the 36‑week Phase 2b ACCESS study and 15.3% at 240 mg in the exploratory ACCESS II study, with class‑consistent gastrointestinal side effects and no reported drug‑induced liver injury or QTc issues. Multiple Phase 2 and extension studies support moving into Phase 3 obesity trials in the second half of 2026.
The company is also advancing oral amylin receptor agonists ACCG‑2671 and ACCG‑3535 into Phase 1, plus early GIP and glucagon receptor programs, while retaining a broad GPCR pipeline. In December 2025, a subsidiary licensed certain non‑core GLP‑1 patents to Genentech and Roche for a $100 million upfront payment and future low single‑digit royalties.